USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Chiron Corp
Address:
4560 Horton St
Emeryville, CA 94608
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $392,129.00 8
SBIR Phase II $967,047.00 3

Award List:

FEEDBACK CONTROLLED OLIGONUCLEOTIDE SYNTHESIZER PHASE I

Award Year / Program / Phase:
1983 / SBIR / Phase I
Award Amount:
$55,200.00
Agency:
HHS
Principal Investigator:
Mickey S. Urdea , Principal Investigator
Abstract:
N/a

FEEDBACK CONTROLLED OLIGONUCLEOTIDE SYNTHESIZER PHASE I

Award Year / Program / Phase:
1984 / SBIR / Phase II
Award Amount:
$221,047.00
Agency:
HHS
Principal Investigator:
Mickey S. Urdea , Principal Investigator
Abstract:
The investigations have proposed the development of an automated oligonucleotide synthesizer incorporating a numberof new features. using phosphite-triester methodology for oligodeoxyribonucleotide syntheses occasionally low yields occasionally low yields are obtained in the condensation step. this… More

IN ORDER TO FACILITATE THE ULTIMATE PRODUCTION OF A DIAGNOSTIC AND VACCINE FOR HUMAN VIRAL NANB HEPATITIS USING RECOMBINANT DNA TECHNOLOGY, STRATEGIES DESIGNED TO ISOLATE VIRAL NUCLEIC ACID WILL BE INITIATED THROUGH THE PRODUCTION OF ENRICHED RECOMBINANT

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Michael houghton , PRINCIPAL INVESTIGATOR
Abstract:
In order to facilitate the ultimate production of a diagnostic and vaccine for human viral nanb hepatitis using recombinant dna technology, strategies designed to isolate viral nucleic acid will be initiated through the production of enriched recombinant cdna libraries and by direct radio-labeling… More

A NEW APPROACH FOR ANTIGEN PRESENTATION AND POLYVALENT VACCINES IS PROPOSED.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$37,095.00
Agency:
HHS
Principal Investigator:
Pablo valenzuela , PRINCIPAL INVESTIGATOR
Abstract:
A new approach for antigen presentation and polyvalent vaccines is proposed. experiments are designed to test the idea of combining the gene of a second immunogen with that of hepatitis b surface antigen (hbsag) such that the second immunogen is assembled into, and presented on, the surface of the… More

GENETIC ENGINEERING APPROACHES FOR AIDS VACCINES (MICE, RABB

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Paul A. Luciw , Principal Investigator
Abstract:
N/a

GENETIC ENGINEERING APPROACHES FOR MALARIA VACCINES

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Philip J Barr , Principal Investigator
Abstract:
N/a

GENETIC ENGINEERING APPROACHES FOR AIDS VACCINES (MICE, RABB

Award Year / Program / Phase:
1987 / SBIR / Phase II
Award Amount:
$246,000.00
Agency:
HHS
Principal Investigator:
Paul A. Luciw , Principal Investigator
Abstract:
We have molecularly cloned, sequenced, and expressed the genes of the retrovirus associated with acquired immune deficiency syndrome (aids), and we have initiated genetic engineering approaches for the development and testing of subunit viral vaccines. the predicted sequence of the viral envelope… More

GENETIC ENGINEERING APPROACHES FOR MALARIA VACCINES

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Philip J Barr , Principal Investigator
Abstract:
This research will develop subunit vaccines for the two predominant species of malaria parasites, plasmodium falciparum and plasmodium vivax. previous studies have shown that: 1. hybrid hepatitis b virus surface antigen (hbvsag) polypeptides (composed of insertions of part of thecircumsporozoite… More

CYTOMEGALOVIRUS GLYCOPROTEIN B RECOMBINANT ANTIGENS

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,961.00
Agency:
HHS
Principal Investigator:
Richard R Spaete
Abstract:
This research will express recombinant forms of human cytomegalovirus (cmv) glycoprotein b (gb) for use in the development of a subunit vaccine against cmv. in vitro mutagenesis and other recombinant dna techniques will be used to generate two forms of gb: (1) an uncleaved gb molecule lacking the… More

DEVELOPMENT OF A CYTOMEGALOVIRUS SUBUNIT VACCINE

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,873.00
Agency:
HHS
Principal Investigator:
Richard R Spaete
Abstract:
Chiron corporation is developing a subunit vaccine directed against human cytomegalovirus (cmv), using recombinant derivatives of viral glycoproteins that are capable of inducing neutralizing antibodies in humans. a candidate antigen for this vaccine is cmv glycoprotein h (gh), which has been shown… More

DEVELOPMENT OF A DEFECTIVE HEPATITIS A VIRUS VACCINE

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Gary A Van Nest
Abstract:
Attempts to generate hepatitis a virus (hav) vaccines have been unsuccessful to date due to several factors, including poor growth of the virus in tissue culture, absence of in vitro markers of attenuation, and the fact that isolated viral proteins do not display virus-neutralizing epitopes. as an… More